LICENSE AND DISTRIBUTION AGREEMENT by and between Immuno-Designed Molecules S.A. and Cambridge Laboratories Ltd.License and Distribution Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations
CAMBRIDGE LABORATORIES LTD. trading as CAMBRIDGE LABORATORIES IRELAND whose principal place of business is Alexandra House, The Sweepstakes, Ballsbridge, Dublin 4, IRELAND.
BY AND BETWEEN THE UNDERSIGNED : AND:Il-13 Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations
SANOFI-SYNTHELABO, a French société anonyme with a capital of 1 462 883 492 Euros having its principal place of business at 174, avenue de France, 75013 Paris, and registered at the Paris Register of Trade and Companies under B 395 030 844, represented by Jean-Claude Leroy, Senior Vice President Strategy and Business Development and José Ferrer, Director Operations Legal Affairs (hereinafter “SANOFI-SYNTHELABO”);
Biotecnol SA AndDevelopment and Manufacturing Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations
LICENSE AGREEMENTLicense Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”) effective as of April 4, 1996 (the “Effective Date”), is entered by and between CIBA-GEIGY Limited, a Swiss corporation, with principal offices at Klybeckstrasse 141, Basel, Switzerland (“Ciba”), and TherAtid, Incorporated, a California corporation, having a principal place of business at 828 Eastbrook Court, Danville, California 94506-1206 (“TherAtid”). All references to TherAtid shall include its Affiliates.
LICENSE AGREEMENTLicense Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations • California
LICENSE AGREEMENT dated December 30, 2005 by and between IDM Pharma, Inc., a Delaware corporation (“IDM”), and Pharmexa, Inc., a Delaware corporation (hereinafter “Pharmexa”) (each, a “Party” and, collectively, the “Parties”).
DIRECTORS’ DEFERRED COMPENSATION PLANDirectors’ Deferred Compensation Plan • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations • California
The Company believes that it is in its best interests to amend and restate this Plan effective as of January 1, 2005 with respect to Post-2004 Deferrals for purposes of compliance with Section 409A of the Internal Revenue Code of 1986, as amended, and its regulations and other guidance thereunder.
ContractAsset Purchase Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations • California
AMENDMENT No. 1 (this “Amendment”), dated as of December 30, 2005, to the Asset Purchase Agreement dated as of November 23, 2005 (the “Agreement”), by and between IDM PHARMA, INC., a Delaware corporation (the “Seller”), and PHARMEXA INC., a Delaware corporation (the “Buyer”). Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Agreement.
ASSET PURCHASE AGREEMENT BETWEEN AND PHARMEXA INC. NOVEMBER 23, 2005Asset Purchase Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations • California
ASSET PURCHASE AGREEMENT, dated, November 23, 2005, by and between IDM Pharma, Inc., a Delaware corporation (“Seller”), and Pharmexa Inc., a Delaware corporation (“Buyer”).
Development Collaboration and Supply Agreement between Medarex, Inc. andDevelopment Collaboration and Supply Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations • New York
This Development Collaboration and Supply Agreement (the “Agreement”) is made and entered into as of May 24, 2002 (the “Effective Date”), by and between Medarex, Inc., a New Jersey corporation, with its principal place of business at 707 State Road #206, Princeton, New Jersey 08540, (“Medarex”), and IDM S.A., a French corporation with its principal place of business at 172 rue de Charonne, 75011 Paris, France (“IDM”).
Restricted Stock Bonus AgreementRestricted Stock Bonus Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations
Pursuant to the Restricted Stock Bonus Grant Notice (“Grant Notice”) and this Restricted Stock Bonus Agreement (collectively, the “Award”) and in consideration of your past services, IDM Pharma, Inc. (the “Company”) has awarded you a stock bonus under its 2000 Stock Plan (the “Plan”) for the number of shares of the Company’s Common Stock subject to the Award as indicated in the Grant Notice. Defined terms not explicitly defined in this Restricted Stock Bonus Agreement but defined in the Plan shall have the same definitions as in the Plan.
LICENSE AGREEMENTLicense Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations • California
LICENSE AGREEMENT dated December 30, 2005 by and between IDM Pharma, Inc., a Delaware corporation (“IDM”), and Pharmexa, Inc., a Delaware corporation (hereinafter “Pharmexa”) (each, a “Party” and, collectively, the “Parties”).
AMENDED AND RESTATED IL-13 LICENSE AGREEMENTIl-13 License Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations
IDM, a French société anonyme with a capital of 1 569 444,60 Euros having its principal place of business at 172 rue de Charonne, Paris (75011) and registered at the Paris Register of Trade and Companies under B 382 632 263 represented by Jean-Loup Romet-Lemonne, President and CEO (hereinafter, “IDM”).
SERVICES AGREEMENTServices Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations • California
THIS SERVICES AGREEMENT (the “Agreement”) is made as of December 30, 2005 (the “Effective Date”) by and between Pharmexa Inc., a Delaware corporation (“Pharmexa”), and IDM Pharma, Inc., a Delaware corporation (“IDM”) (each a “Party” and together, the “Parties”).
MEMORANDUM OF AGREEMENTMemorandum of Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations
SANOFI-SYNTHELABO, a French société anonyme with a capital of 1 462 883 492 Euros having its principal place of business at 174, avenue de France, 75013 Paris, and registered at the Paris Register of Trade and Companies under B 395 030 844, represented by Jean-Claude Leroy, Senior Vice President Strategy and Business Development and José Ferrer, Director Operations Legal Affairs (hereinafter “SANOFI-SYNTHELABO”);
